SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020

SMi Group 15 - 16 January 2020, London, UK.
SMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London. As Europe's leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.

With the rapid expansion of the PFS market, the regulatory environment is more importance than ever. This year's programme will look at the EU MDR, Article 117 as well as insights into the MDR post-market surveillance requirements; providing a holistic review of the Pre-Filled Syringes industry.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior Pre-Filled Syringes Engineers, Device Testing Managers, Heads of Late-Stage Pre-Filled Syringes Development, Head of Medical Affairs, Senior Director - Combination Products & Medical Devices, Global Regulatory Affairs, Quality Assurance Manager Combination Products, Senior Pharmaceutical Assessor and many more.

Benefits of attending

  • Learn about the technological innovations that are revolutionizing the injectable drug delivery space through novel device design
  • Debate how can we prepare for the regulatory impact of Brexit and the EU MDR on devices
  • Hear industry experts uncovering the latest advancements optimizing drug biologics to improve PFS delivery
  • Assess industry case studies exploring how to overcome challenges of extractables and leachables

Chairs for 2019

  • James Mellman, Device Manager, Novartis
  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured speakers

  • Abha Raveau-Violette, Device Manager, AstraZeneca
  • Amanda Matthews, Senior Director, Pfizer
  • Anil-Kumar Busimi, Strategy and Innovation, Senior Global Product Manager, SCHOTT
  • Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Cedric Gysel, Healthcare Solutions Manager, Johnson & Johnson
  • Cinzia Rotella, Senior Materials Scientist, Sanofi
  • Clemens Guenther, Director Nonclinical Safety Consumer Care, Bayer
  • Colin Roscoe, Principal Human Factors Scientist, Teva Pharmaceuticals
  • Hiroki Hasegawa, Researcher, Mitsubishi Gas Chemical Company, Inc
  • James Mellman, Device Manager, Novartis A G
  • Kewei Yang, Pharmaceutical Scientist, Roche
  • Khaudeja Bano, Head of Medical Devices, Abbott Molecular Inc
  • Marion Westwood, Pharmaceutical Assessor, Medicines & Healthcare products Regulatory Agency (MHRA)
  • Matthew Nicolas, Investigator, GlaxoSmithKline
  • Nicolas Eon, Senior Global Product Manager, SCHOTT
  • Olaf Lebau, Design Engineer for Medical Devices and Combination Products, Boehringer Ingelheim GmbH
  • Raphael Nudelman, Director of Chemical and Computational Toxicology, Teva Pharmaceuticals
  • Remy Vomscheid, Director, Devices Development & Technologies, IPSEN Pharmsciences
  • Torsten Kneuss, Quality Assurance Manager Combination Products, Bayer Pharma

Plus, pre-conference workshop day will be taking place on 14th January in London:

Workshop A: A Roadmap to Regulation Quality Management Systems and Technical Standards
Workshop B: Testing Requirements of Pre-Filled Syringes led by Horst Koller, CEO, HK Packaging Consulting GmbH
Workshop C: Extractables and Leachables: Considerations for PFS Platforms

For more information and to register, please visit:
http://www.pre-filled-syringes.com/wpnwl

Early-Bird Rates

  • Register by 29th November to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...